Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 17, 2004. The report details corporate actions regarding share repurchases and updates on directors' interests in company securities.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes and treasury share holdings.
- Treasury Shares Held: 68,948,000 (as of December 17, 2004).
- Shares in Issue (excluding treasury): 5,868,432,035 (as of December 17, 2004).
- Share Repurchase Price (Dec 17): 1,177.54 pence per share.
- Share Repurchase Price (Dec 16): 1,187.68 pence per share.
Material Changes
The primary material changes involve the reduction of outstanding shares through open market repurchases authorized by shareholders at the May 17, 2004 Annual General Meeting.
- December 17, 2004: Purchased 1,500,000 Ordinary Shares.
- December 16, 2004: Purchased 1,000,000 Ordinary Shares.
- Total Repurchased in Period: 2,500,000 Ordinary Shares.
- Employee Trust Activity: The GSK Trust transferred 6,084 shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- US Retirement Plan: The number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan decreased from 18,743,733 to 18,660,462 due to fund movements.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a statutory disclosure of specific transactions.
Investor Verification Checklist
- Verify the total number of treasury shares held (68,948,000) against the company's latest capitalization table.
- Confirm the weighted average price paid for the 2.5 million shares repurchased in mid-December 2004.
- Review the impact of the share repurchases on earnings per share (EPS) in subsequent quarterly reports.
- Check for any further disclosures regarding the GSK Trust or US Retirement Savings Plan holdings in future filings.